BioAmber Inc. is in the process of becoming a major player in the biobased succinic acid production market following its recent IPO. It is still at least six quarters away from achieving commercial-scale production, however, and the novelty of its pathway makes its commercialization prospects relatively uncertain. While management is optimistic that the company will achieve commercial-scale production by 2015, investors should be aware that the process is very uncertain and the risk of reductions to shareholder equity along the way is not low.
BioAmber Inc. (BIOA) is a producer of biobased succinic acid. It is one of the newest additions to the ranks of publicly-traded companies that has opted to use biotechnology to produce...
Only subscribers can access this article, which is part of the PRO research library covering 3,758 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: